NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA), Sonic Automotive, Inc. (NYSE:SAH), Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), and Clovis Oncology, Inc. (NASDAQ:CLVS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

KALV DOWNLOAD: http://Fundamental-Markets.com/register/?so=KALV IZEA DOWNLOAD: http://Fundamental-Markets.com/register/?so=IZEA SAH DOWNLOAD: http://Fundamental-Markets.com/register/?so=SAH CATB DOWNLOAD: http://Fundamental-Markets.com/register/?so=CATB ANIP DOWNLOAD: http://Fundamental-Markets.com/register/?so=ANIP CLVS DOWNLOAD: http://Fundamental-Markets.com/register/?so=CLVS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA), Sonic Automotive, Inc. (NYSE:SAH), Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), and Clovis Oncology, Inc. (NASDAQ:CLVS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed August 23rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

KALVISTA PHARMACEUTICALS, INC. (KALV) REPORT OVERVIEW

KalVista Pharmaceuticals' Recent Financial Performance

For the three months ended April 30th, 2018 vs April 30th, 2017, KalVista Pharmaceuticals reported revenue of $4.84MM vs $1.24MM (up 289.69%) and basic earnings per share -$0.03 vs $1.74. For the twelve months ended April 30th, 2018 vs April 30th, 2017, KalVista Pharmaceuticals reported revenue of $8.39MM vs $1.50MM (up 458.11%) and basic earnings per share -$1.53 vs -$4.47. KalVista Pharmaceuticals is expected to report earnings on September 13th, 2018. The report will be for the fiscal period ending July 31st, 2018. The reported EPS for the same quarter last year was -$0.51.

To read the full KalVista Pharmaceuticals, Inc. (KALV) report, download it here: http://Fundamental-Markets.com/register/?so=KALV

-----------------------------------------

IZEA INC. (IZEA) REPORT OVERVIEW

IZEA's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, IZEA reported revenue of $4.12MM vs $5.71MM (down 27.87%) and basic earnings per share -$0.28 vs -$0.25. For the twelve months ended December 31st, 2017 vs December 31st, 2016, IZEA reported revenue of $24.44MM vs $21.23MM (up 15.09%) and basic earnings per share -$0.96 vs -$1.41. IZEA is expected to report earnings on November 6th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.10. The estimated EPS forecast for the next fiscal year is $0.28 and is expected to report on April 17th, 2019.

To read the full IZEA Inc. (IZEA) report, download it here: http://Fundamental-Markets.com/register/?so=IZEA

-----------------------------------------

SONIC AUTOMOTIVE, INC. (SAH) REPORT OVERVIEW

Sonic Automotive's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Sonic Automotive reported revenue of $2,505.75MM vs $2,405.75MM (up 4.16%) and basic earnings per share $0.40 vs $0.27 (up 48.15%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sonic Automotive reported revenue of $9,867.21MM vs $9,731.78MM (up 1.39%) and basic earnings per share $2.11 vs $2.04 (up 3.43%). Sonic Automotive is expected to report earnings on October 23rd, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.40. The estimated EPS forecast for the next fiscal year is $2.02 and is expected to report on February 26th, 2019.

To read the full Sonic Automotive, Inc. (SAH) report, download it here: http://Fundamental-Markets.com/register/?so=SAH

-----------------------------------------

CATABASIS PHARMACEUTICALS, INC. (CATB) REPORT OVERVIEW

Catabasis Pharmaceuticals' Recent Financial Performance

Catabasis Pharmaceuticals is expected to report earnings on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.31. The estimated EPS forecast for the next fiscal year is -$0.67 and is expected to report on March 21st, 2019.

To read the full Catabasis Pharmaceuticals, Inc. (CATB) report, download it here: http://Fundamental-Markets.com/register/?so=CATB

-----------------------------------------

ANI PHARMACEUTICALS, INC. (ANIP) REPORT OVERVIEW

ANI Pharmaceuticals' Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, ANI Pharmaceuticals reported revenue of $47.27MM vs $44.76MM (up 5.59%) and basic earnings per share $0.24 vs $0.23 (up 4.35%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ANI Pharmaceuticals reported revenue of $176.84MM vs $128.62MM (up 37.49%) and basic earnings per share -$0.09 vs $0.34. ANI Pharmaceuticals is expected to report earnings on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $1.03. The estimated EPS forecast for the next fiscal year is $5.67 and is expected to report on February 26th, 2019.

To read the full ANI Pharmaceuticals, Inc. (ANIP) report, download it here: http://Fundamental-Markets.com/register/?so=ANIP

-----------------------------------------

CLOVIS ONCOLOGY, INC. (CLVS) REPORT OVERVIEW

Clovis Oncology's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Clovis Oncology reported revenue of $23.76MM vs $14.62MM (up 62.50%) and basic earnings per share -$1.94 vs -$3.88. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Clovis Oncology reported revenue of $55.51MM vs $0.08MM (up 71,067.95%) and basic earnings per share -$7.36 vs -$9.07. Clovis Oncology is expected to report earnings on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$1.24. The estimated EPS forecast for the next fiscal year is -$4.49 and is expected to report on February 25th, 2019.

To read the full Clovis Oncology, Inc. (CLVS) report, download it here: http://Fundamental-Markets.com/register/?so=CLVS

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Andrew Duffie, Media Department Office: +1 667-401-0010 E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.